Roel Bulthuis
life sciences
Calypso Biotech
India
Biography
Roel Bulthuis is Head of MS Ventures, the strategic venture capital group of Merck Serono, which he established in 2009. ​Through the ventures group, Merck Serono is committed to actively invest in emerging biotech companies which have the potential to provide innovative products in Merck Serono’s core therapeutic areas, or access to innovative technologies.​ MS Ventures also manages the Merck Serono Israel BioIncubator Fund. ​Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before that, he worked at Devgen in Ghent, Belgium. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.
Research Interest
Roel Bulthuis is Head of MS Ventures, the strategic venture capital group of Merck Serono, which he established in 2009. ​Through the ventures group, Merck Serono is committed to actively invest in emerging biotech companies which have the potential to provide innovative products in Merck Serono’s core therapeutic areas, or access to innovative technologies.​ MS Ventures also manages the Merck Serono Israel BioIncubator Fund. ​Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before that, he worked at Devgen in Ghent, Belgium. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.
